辉粒药业

Huili Pharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of high-end complex injectable formulations. The company utilizes its proprietary high-performance microsphere preparation technology to create long-acting versions of established therapeutic agents, aiming to enhance patient compliance and clinical outcomes. Their research and development efforts are primarily focused on chronic conditions within the central nervous system, metabolic diseases, and oncology. Huili Pharma's lead programs include long-acting microsphere formulations of risperidone for schizophrenia and exenatide for type 2 diabetes. The company maintains an in-house GMP-compliant manufacturing facility to support the production of its microsphere-based pipeline from clinical trials through commercialization.